Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20473276 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL20473336 | 0.93 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL28905494 | 0.93 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL21272145 | 0.90 | MAPT (0.49) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL21272147 | 0.90 | MAPT (0.49) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL29601910 | 0.89 | CTSS (0.41) | SMN1; SMN2ALDH1A1GAAMAPTPPARG | |
| SCHEMBL20473299 | 0.89 | CTSS (0.41) | SMN1; SMN2ALDH1A1GAAMAPTPPARG | |
| SCHEMBL21272211 | 0.88 | MAPT (0.51) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL21272208 | 0.88 | MAPT (0.51) | SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL20473233 | 0.87 | CCR9 (0.45) | SMN1; SMN2ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-11-01 | — | — | US | disclosed |
| EP-3363801-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017101808-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | GABRA5, GABRA1, GABRA6 | SMN1; SMN2 3525/4885ALDH1A1 464/4885GAA 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.